Company: BWAY
Filing Date: 2025-09-30
Form Type: 6-K
Source: 0001171843-25-006185
Chunk: 6

Company: Brainsway Ltd.
Filing Date: 2025-09-30
Form: 6-K
Chunk 6
---
 for adult patients suffering from OCD, and a clearance from the FDA
in August 2020 for use of its Deep TMS system as an aid in short-term smoking cessation in adults.

The Company and its wholly owned subsidiaries, BrainsWay,
Inc. (“Inc”), Brain R&D Services Ltd. (“Brain R&D”), BrainsWay USA Inc (“USA Inc”) and Tikva
LLC (“Tikva”), (collectively the “Group”) derive revenues from the sale and lease of its systems and from related
services.

| b. | Tikva LLC, a wholly owned subsidiary of Brainsway Inc., formed in Delaware in 2025 in 
 order to facilitate certain strategic investments in the U.S.                         |

| c. | The Company has a net profit of $3,134 for the six months ended June 30, 2025. The company’s                                              
 management and board of directors believe that the Company has sufficient funding to finance its business activity according to its plans 
 in the foreseeable future.                                                                                                                |

| e. | U.S. President Trump’s tariff plan: |

In April 2025, the Trump Administration
announced a government plan which imposes reciprocal tariffs on the import of goods from numerous countries into the U.S. The overall
tariff on the import of goods from Israel to the U.S. is 17%. The tariff applies solely to the import of goods and not to the import of
services. While the Company does not believe that its first half 2025 financial results were materially affected by these developments,
economic uncertainty may have an impact on the Company’s market and sales in the USA. If substantial tariffs remain in place, the
Company may begin to see a reduction in US sales and in US revenues. Although the impact of the tariffs is difficult to predict with any
certainty, the Company is actively evaluating its options and potential steps that may mitigate the impact of such trade-related circumstances
and the impact of trade policy changes on future results remains uncertain.

NOTE 2: ACCOUNTING POLICIES

Basis of presentation of the financial statements:

These condensed consolidated unaudited interim Financial
Statements have been prepared in accordance with IAS 34, “Interim Financial Reporting”. They do not include all of the
information required for annual Financial Statements and should be read in conjunction with the consolidated Financial Statements of the
Company as at and for the year ended December 31, 2024 (hereafter – the “annual Financial Statements”). These condensed